Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The bone-marrow infiltration pattern in B-cell chronic lymphocytic leukemia is not an important prognostic factor. Danish CLL Study Group.
Geisler CH, Hou-Jensen K, Jensen OM, Tinggaard-Pedersen N, Hansen MM, Hansen NE, Holm M, Christensen BE, Drivsholm A, Nielsen JB, Thorling K, Andersen E, Larsen JK, Anderson PK. Geisler CH, et al. Among authors: drivsholm a. Eur J Haematol. 1996 Oct;57(4):292-300. doi: 10.1111/j.1600-0609.1996.tb01380.x. Eur J Haematol. 1996. PMID: 8982292
In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients.
Geisler CH, Philip P, Christensen BE, Hou-Jensen K, Pedersen NT, Jensen OM, Thorling K, Andersen E, Birgens HS, Drivsholm A, Ellegaard J, Larsen JK, Plesner T, Brown P, Andersen PK, Hansen MM. Geisler CH, et al. Among authors: drivsholm a. Leuk Res. 1997 Nov-Dec;21(11-12):1011-23. doi: 10.1016/s0145-2126(97)00095-7. Leuk Res. 1997. PMID: 9444933
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP, Pedersen-Bjergaard J, Ellegaard J, Brincker H, Boesen AM, Christensen BE, Drivsholm A, Hippe E, Jans H, Jensen KB, et al. Hansen OP, et al. Among authors: drivsholm a. Leukemia. 1991 Jun;5(6):510-6. Leukemia. 1991. PMID: 2056774 Clinical Trial.
Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG).
Keldsen N, Bjerrum OW, Dahl IM, Drivsholm A, Ellegaard J, Gadeberg O, Gimsing P, Grønvold T, Hansen MM, Hippe E, et al. Keldsen N, et al. Among authors: drivsholm a. Eur J Haematol. 1993 Aug;51(2):80-5. doi: 10.1111/j.1600-0609.1993.tb01597.x. Eur J Haematol. 1993. PMID: 8370422 Clinical Trial.
Current patterns of bacterial infection in myelomatosis.
Espersen F, Birgens HS, Hertz JB, Drivsholm A. Espersen F, et al. Among authors: drivsholm a. Scand J Infect Dis. 1984;16(2):169-73. doi: 10.3109/00365548409087137. Scand J Infect Dis. 1984. PMID: 6740248
45 results